Drugs.com FDA Alerts · 11/9/2026
FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition
Audience: Consumer, Patient, Health Care Professional, Pharmacy, Ophthalmology November 9, 2026 -- The U.S. Food and Drug Administration is informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic...
Why this is tracked
This item matched GLP-1, Medicare, Part D, CMS, FDA, coverage, pricing, prior authorization, or access terms used by the daily monitor.
Read the source
This page summarizes and links to the original source. Use the source article, CMS/FDA notices, plan documents, and clinician guidance for decisions.